Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Growth hormone therapy will improve the height of idiopathic short statured children.
DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to
non-treatment group in efficacy and safety.